TY - JOUR T1 - Prognostic Value of Adjuvant Chemotherapy Following Pancreaticoduodenectomy in Elderly Patients With Pancreatic Cancer JF - Anticancer Research JO - Anticancer Res SP - 1005 LP - 1012 DO - 10.21873/anticanres.13206 VL - 39 IS - 2 AU - SANG HYUN SHIN AU - YEJONG PARK AU - DAE WOOK HWANG AU - KI BYUNG SONG AU - JAE HOON LEE AU - JAEWOO KWON AU - CHANGHOON YOO AU - SHADI ALSHAMMARY AU - SONG CHEOL KIM Y1 - 2019/02/01 UR - http://ar.iiarjournals.org/content/39/2/1005.abstract N2 - Background/Aim: The aim of this study was to investigate the relationship between age and long-term survival among patients who underwent pancreaticoduodenectomy (PD) for pancreatic ductal adenocarcinoma (PDAC). Patients and Methods: A total of 916 patients who underwent PD for curative resection of PDAC were included in this study. Patients were divided into younger (n=726, <70 years) and older (n=190, ≥70 years), and the overall survival (OS) between the two groups was compared. Results: Median OS was significantly longer in the younger group (p<0.001). However, the survival advantage among younger patients was not significant when analyzing only patients who received adjuvant chemotherapy (p=0.548). Among patients who did not receive adjuvant chemotherapy, OS was significantly longer in the younger group (p=0.003). Among patients who received neither adjuvant chemotherapy nor treatment for recurrence, survival was not significantly different between the groups (p=0.629). Conclusion: Adjuvant chemotherapy should be recommended, and additional treatment for recurrence is effective even among elderly who have not received adjuvant chemotherapy. ER -